Patent exclusivity and biosimilars: what’s a reasonable compromise?

The biotech industry, through the Biotechnology Industry Organization (BIO), has been arguing in favor of a 12-year exclusivity period for new biological agents from the initial date of approval.

Hyperbole, hysteria, and health care reform

The idea that we might all try to cooperate and collaborate in the interests of developing a new and better health care system that serves the needs of all Americans appears to be vanishing rapidly out of the windows of buildings in Washington. Perhaps the best we can now hope is that the pragmatism for [...]